Immunotherapy regimens for metastatic colorectal carcinomas

Immunotherapy regimens for metastatic colorectal carcinomas

Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related mortality with a 5-year overall survival rate of 13%. Despite recent advances in cancer immunotherapy, only the minority of CRC patients (<15%) with microsatellite instability can potentially benefit from immune checkpoint i...

Full description

Bibliographic Details
Main Authors: Babar Bashir, Adam E. Snook
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
colorectal cancer
cancer immunotherapy
cancer vaccines
checkpoint inhibitors
microsatellite instability
Online Access:http://dx.doi.org/10.1080/21645515.2017.1397244

Internet

http://dx.doi.org/10.1080/21645515.2017.1397244

Similar Items